BriaCell Therapeutics (TSE:BCT) has released an update.
BriaCell Therapeutics has presented promising survival data from its Phase 2 trial for metastatic breast cancer patients, showcasing double the median overall survival compared to literature benchmarks. The treatment regimen, which includes the Bria-IMT™ and a checkpoint inhibitor, has shown particular effectiveness in patients with central nervous system metastases, sparking optimism for future applications. With no treatment-related discontinuations reported, the company is hopeful about replicating these results in their ongoing Phase 3 study.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.